Connecting the dots of Nagakute City – ジブリと里山、文化と歴史がある長久手のWebメディア

「長湫警固祭り」❶ 開催2026・秋/今年から女性も”鉄砲隊”へ参加!棒の手は2023年から参加中!【Nagakute Times】

毎年10月の「警固祭り」の朝は、長久手市民にとっては特別の朝になる
今年の秋は、長久手西部・南部地区の「長湫警固祭り」(県指定無形民俗文化財)が開催されました

新住民にとっては驚きの朝になったのではないか。早朝7時に火縄銃の発砲音が市内に轟くのだ。
今年は、住宅地が密集する「長湫地区」のこと、住民たちの声を諸々聞き入れ調整がなされたようで、前回の2023年よりも2時間程遅くの9時過ぎに「火縄銃」の爆音が鳴り出した(8時台に準備のための発砲あり)

「警固祭り」の「警固」とは、神の依代のダシ飾りを乗せた神の使いの「神馬」を鉄砲隊と棒隊が警固するという意味
尾張と西三河に戦国時代から伝わるという豊年感謝の祭りでだ
現在まで継承されているのは長久手や瀬戸他、かなり少なくなり、あらためて注目されています

景行天皇社の大鳥居の手前にて、「東切り」と「西切り」の隊列が合流し(出会い)、挨拶を交わします

東切と西切の2つの地区の隊列が長湫地区を練り歩いた後(下に掲載の地図参照)に景行天皇社の大鳥居前で合流(出会い)
祭りの儀式を見ると当に古くから伝わるであろうと推測されます(警固祭りの発祥は戦国時代とされる)
稲のできが豊年の見通しがつくと協議が行われお伺いを立てる慣わしが長く続いたようです。中老が今年は豊作でないので中止にしろと伝えると若い衆が再度協議をし再び中老に相談したり、大老に相談に行ったりしていたそうです。

”出会い”の儀式が終わると、東切りと西切りが鳥居をくぐって境内へと登っていきます

境内へと登り、神馬とともに境内を周り勇ましく疾走。この後に棒の手が奉納されます。

長久手には3地区の警固祭りがあり、その3つが毎年持ち回りで催される
今年は愛知県の無形民俗文化財に指定されている長湫(ながくて)地区が担った

今回は西切りの馬宿は北小学校校庭、東切り馬宿は鴨田公園でした
以前は、より西側の住宅街に近くにある仲作田公園や太平公園横の路上でも発砲されていましたが、諸々調整され今回は後山公園横の路上での発砲となっています
地図:長久手市ホームページ・警固祭りより引用

今回女性として初めて参加した浅井柚伎さん(27歳)
「なんとかやり切りました! 爆音が体に響き、火縄銃重かったですがとにかく嬉しかったです! 家にずっと伝わってきた火縄銃を撃つことは小さい頃から憧れでした」(今回、浅井さん始め大学生の女性と30代の女性の計3名の女性が初めて参加されました)

今回初めて「鉄砲隊」に参加した吉村直彦さん(郷土史研究会会長)
「1ヶ月前から早朝に起き1時間歩いたり体づくりしました。第六分会では最長老だったとのこと。皆さんに助けられほんとうに素晴らしい経験となりました!」

「警固祭り」の”敬固”とは、神の依代のダシ飾りを付けた神馬の周りを固めることをいう
鉄砲隊と棒隊が神馬の周りを警護役となって固めている

神馬と景行天皇社・拝殿と本殿
子供たちも神馬に食べ物を与えていた

この記事を書いた人
1960年 長久手生まれ。上郷保育園、長久手小学校、長久手中学校へ。菊里高校、青山学院大学英米文学科卒。英字新聞部「青山トロージャン」所属。編集プロダクションのMatsuoka & Associatesにて学び、編集工学研究所入所。 1990年、洋書写真集・美術書をリースするArt Bird Books設立、1992年中目黒駅前に店舗を構える。2009年から代官山蔦屋書店にて主に写真集のブックコンシェルジェとして勤務。2020年、Uターンで地元長久手に戻る。 『Canon Photo Circle』誌の写真集コラムを1年間連載後、「長久手タイムズ」を始動。 mail address:nagakutetimes@gmail.com
コメント (118)
  1. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  2. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  3. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  4. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  5. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  6. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  7. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  8. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  9. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  10. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  11. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  12. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  13. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  14. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  15. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  16. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  17. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  18. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  19. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  20. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  21. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  22. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  23. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  24. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  25. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  26. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  27. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  28. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  29. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  30. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  31. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  32. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  33. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  34. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  35. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  36. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  37. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  38. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  39. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  40. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  41. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  42. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  43. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  44. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  45. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  46. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  47. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  48. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  49. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  50. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  51. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  52. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  53. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  54. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  55. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  56. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  57. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  58. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  59. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  60. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  61. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  62. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  63. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  64. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  65. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  66. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  67. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  68. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  69. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  70. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  71. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  72. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  73. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  74. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  75. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  76. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  77. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  78. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  79. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  80. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  81. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  82. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  83. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  84. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  85. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  86. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  87. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  88. Appreciate the well-researched medical context provided here. The comparative evaluation of generic formulations versus branded standards highlights critical purity and manufacturing metrics.

  89. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  90. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  91. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  92. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  93. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  94. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  95. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  96. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  97. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  98. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  99. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  100. Very detailed and objective assessment. The points raised concerning therapeutic index monitoring and safe long-term protocols are essential for anyone evaluating these compounds.

  101. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  102. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  103. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  104. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  105. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  106. This protocol breakdown addresses several vital clinical aspects regarding dosage safety, contraindications, and sustained efficacy over extended regimens. Very helpful reference!

  107. Excellent summary of key safety markers and clinical application guidelines. The distinction between dosage strengths and individualized patient response curves is spot-on.

  108. A remarkably comprehensive overview of clinical utility and proper administration protocols. The emphasis on quality assurance and verified sourcing standards is well-timed.

  109. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  110. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  111. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  112. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

  113. Thank you for sharing this thorough clinical review. The analysis of therapeutic dosing, patient adherence guidelines, and physiological efficacy provides much-needed clarity for researchers.

  114. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  115. Thank you for this detailed informational perspective. The breakdown of active pharmacokinetics and safety monitoring protocols provides a robust reference for healthcare research.

  116. An exceptionally clear and evidence-based analysis. The structured recommendations for mitigating potential adverse interactions and monitoring baseline metrics are invaluable.

  117. Great insights on pharmacokinetic bioavailability and active compound titration. It is refreshing to see such detailed pharmacological breakdowns rather than generic summaries.

  118. Very insightful commentary on treatment timelines and optimal therapeutic thresholds. Clear, concise, and academically sound review of the active mechanisms involved.

コメントを残す

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です